Bayer signs €50m deal for Orion's prostate cancer drug
Bayer is paying €50m upfront to Finland's Orion for ODM-201, its prostate cancer drug, which is due to start a Phase III trial later this year.
Bayer is paying €50m upfront to Finland's Orion for ODM-201, its prostate cancer drug, which is due to start a Phase III trial later this year.